328 related articles for article (PubMed ID: 8175019)
1. Neoadjuvant chemotherapy for advanced ovarian cancer.
Schwartz PE; Chambers JT; Makuch R
Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.
Schwartz PE; Rutherford TJ; Chambers JT; Kohorn EI; Thiel RP
Gynecol Oncol; 1999 Jan; 72(1):93-9. PubMed ID: 9889037
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
5. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
[TBL] [Abstract][Full Text] [Related]
6. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
Tkácová M; Vertaková-Krakovská B; Belohorská B; Miskovská V; Helpianska L; Ondrus D; Ondrusová M; Spánik S; Svec J
Klin Onkol; 2009; 22(6):273-7. PubMed ID: 20099745
[TBL] [Abstract][Full Text] [Related]
7. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
[TBL] [Abstract][Full Text] [Related]
8. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
9. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
11. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
14. The role of optimal debulking in advanced stage serous carcinoma of the uterus.
Moller KA; Gehrig PA; Van Le L; Secord AA; Schorge J
Gynecol Oncol; 2004 Jul; 94(1):170-4. PubMed ID: 15262137
[TBL] [Abstract][Full Text] [Related]
15. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
16. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
17. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
18. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
